| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14737159.2016.1156533 |
| P698 | PubMed publication ID | 26895074 |
| P2093 | author name string | Pei Hui | |
| Natalia Buza | |||
| James Ziai | |||
| P2860 | cites work | Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. | Q47351066 |
| Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type. | Q47645513 | ||
| Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome | Q47762736 | ||
| Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types | Q47795729 | ||
| BRAF V600E Mutation Analysis Simplifies the Testing Algorithm for Lynch Syndrome | Q47906055 | ||
| Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients | Q47927589 | ||
| Microsatellite Instability Is Associated With a Better Prognosis for Gastric Cancer Patients After Curative Surgery | Q48667067 | ||
| Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations | Q48746431 | ||
| More differences between HNPCC-related and sporadic carcinomas from the endometrium as compared to the colon | Q49179255 | ||
| Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer | Q50190926 | ||
| The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. | Q50601473 | ||
| Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome | Q50776571 | ||
| Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center | Q51048185 | ||
| Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer | Q51069195 | ||
| Endometrial cancer patients and compliance with genetic counseling: room for improvement | Q51526342 | ||
| Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands | Q51604498 | ||
| Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation | Q51772302 | ||
| Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities | Q51803437 | ||
| Most low-level microsatellite instability in colorectal cancers can be explained without an elevated slippage rate | Q51887591 | ||
| Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer | Q51916596 | ||
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer | Q52846071 | ||
| Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome | Q53085005 | ||
| Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. | Q54557511 | ||
| Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. | Q54703703 | ||
| New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. | Q55033068 | ||
| The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer | Q58635831 | ||
| Molecular Analysis of Familial Endometrial Carcinoma: A Manifestation of Hereditary Nonpolyposis Colorectal Cancer or a Separate Syndrome? | Q59244843 | ||
| Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance | Q47243772 | ||
| Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds | Q24535557 | ||
| Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
| Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability | Q24618618 | ||
| Comparative genomics and molecular dynamics of DNA repeats in eukaryotes | Q24650948 | ||
| EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome | Q24655053 | ||
| The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations | Q24655454 | ||
| Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences | Q24813458 | ||
| BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer | Q28239788 | ||
| Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer | Q28253384 | ||
| Colorectal cancer due to deficiency in DNA mismatch repair function: a review | Q28262308 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Genetic mapping of a locus predisposing to human colorectal cancer | Q28268634 | ||
| SnapShot: DNA mismatch repair | Q28282722 | ||
| Risks of Lynch syndrome cancers for MSH6 mutation carriers | Q30492977 | ||
| Cancer risks for MLH1 and MSH2 mutation carriers | Q30563768 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data | Q33631924 | ||
| Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. | Q33738168 | ||
| Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers | Q33795280 | ||
| Mammalian DNA mismatch repair | Q33847720 | ||
| Risk of pancreatic cancer in families with Lynch syndrome | Q33880380 | ||
| Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene | Q33904639 | ||
| Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree | Q33945201 | ||
| Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. | Q33947093 | ||
| Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome | Q34017044 | ||
| Abundant raw material for cis-regulatory evolution in humans | Q34157325 | ||
| Clinicopathological and genetic features of Chinese hereditary nonpolyposis colorectal cancer (HNPCC). | Q34174654 | ||
| Deficient DNA mismatch repair: a common etiologic factor for colon cancer | Q34189020 | ||
| Hereditary factors in cancer. Study of two large midwestern kindreds | Q34241416 | ||
| Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers | Q34289520 | ||
| Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers | Q34346668 | ||
| Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies | Q34362289 | ||
| Simple sequence repeats in proteins and their significance for network evolution | Q34395163 | ||
| Microsatellite instability generates diversity in brain and sociobehavioral traits | Q34425322 | ||
| Cancer risk in mutation carriers of DNA-mismatch-repair genes | Q34502900 | ||
| The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome | Q34533276 | ||
| Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome | Q34543387 | ||
| Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer | Q34545510 | ||
| Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). | Q34557362 | ||
| Prostate cancer incidence in males with Lynch syndrome | Q34901622 | ||
| Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database | Q34961153 | ||
| DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers | Q34996982 | ||
| Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America | Q35023943 | ||
| Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. | Q35063442 | ||
| Role of DNA mismatch repair defects in the pathogenesis of human cancer | Q35085461 | ||
| Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer | Q35181103 | ||
| BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing | Q35446668 | ||
| A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients | Q35596050 | ||
| Histopathological identification of colon cancer with microsatellite instability | Q35746344 | ||
| Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis | Q35790157 | ||
| Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6 | Q35836701 | ||
| Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study | Q35925149 | ||
| Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results | Q35925275 | ||
| Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database | Q35940640 | ||
| MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study | Q36035692 | ||
| ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing | Q36081155 | ||
| Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications | Q36396727 | ||
| Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach | Q36646164 | ||
| Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing | Q36734614 | ||
| Elevated risk of prostate cancer among men with Lynch syndrome | Q36810712 | ||
| Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts | Q36824964 | ||
| Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours | Q36896145 | ||
| Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. | Q36929974 | ||
| The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. | Q37064547 | ||
| Deficient mismatch repair system in patients with sporadic advanced colorectal cancer | Q37081098 | ||
| Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients | Q37098318 | ||
| Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome | Q37103142 | ||
| Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology | Q37128242 | ||
| Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas | Q37164481 | ||
| Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis | Q37221791 | ||
| Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers | Q37288374 | ||
| Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? | Q37345971 | ||
| Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives | Q37345978 | ||
| Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome | Q37399783 | ||
| Identification of Lynch syndrome among patients with colorectal cancer | Q37416078 | ||
| Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry | Q37537200 | ||
| Reflex testing for Lynch syndrome: if we build it, will they come? Lessons learned from the uptake of clinical genetics services by individuals with newly diagnosed colorectal cancer (CRC). | Q37589534 | ||
| BRAFmutation testing in clinical practice | Q37988572 | ||
| EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients | Q38069531 | ||
| Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. | Q38096698 | ||
| Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review | Q38123671 | ||
| The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy | Q38229658 | ||
| Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer | Q38544933 | ||
| Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas | Q39045081 | ||
| Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry | Q39514722 | ||
| The Muir-Torre syndrome: A 25-year retrospect | Q40439266 | ||
| Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. | Q40687159 | ||
| Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk | Q41685035 | ||
| Constitutional mismatch repair-deficiency syndrome | Q42793022 | ||
| Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin | Q43260542 | ||
| ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). | Q43893519 | ||
| Distinct clinical features and outcomes of gastric cancers with microsatellite instability | Q44028985 | ||
| Interobserver variability in the evaluation of mismatch repair protein immunostaining. | Q44193701 | ||
| Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma | Q44761790 | ||
| Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). | Q45345439 | ||
| Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. | Q45933487 | ||
| P433 | issue | 5 | |
| P921 | main subject | DNA mismatch repair | Q2984243 |
| P304 | page(s) | 591-604 | |
| P577 | publication date | 2016-02-19 | |
| P1433 | published in | Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare | Q15756305 |
| P1476 | title | Mismatch repair deficiency testing in clinical practice | |
| P478 | volume | 16 |
| Q59411242 | Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing |
| Q57143867 | Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy |
| Q60949871 | Data-Driven Discovery of Immune Contexture Biomarkers |
| Q104802091 | Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer |
| Q92610418 | Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients |
| Q92303085 | Is immunohistochemistry-based screening for Lynch syndrome in endometrial cancer effective? The consent's the thing |
| Q49959979 | MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia |
| Q93161798 | Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation |
| Q92281997 | Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability |
| Q58700723 | Molecular Diagnostics in Clinical Oncology |
| Q89878532 | PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer |
| Q41582512 | The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma |
| Q90276254 | Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3 |
Search more.